Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults

Clinica Chimica Acta

Volumn 332, Issue 1-2, 2003, Pages 123-132

  Miles, Michael V ^a   Horn, Paul S ^b   Morrison, John A ^a   Tang, Peter H ^a   DeGrauw, Ton ^a   Pesce, Amadeo J ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Biomarker; Coenzyme Q10; Oxidative stress; Reference interval; Ubiquinol; Ubiquinone

Indexed keywords

UBIDECARENONE;

ADULT; ARTICLE; BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; REFERENCE VALUE; SEX; STATISTICAL SIGNIFICANCE;

PIERINAE;

EID: 0038324376     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00137-2     Document Type: Article

References (70)

1. Crane F.L., Navas P. The diversity of coenzyme Q function. Mol. Aspects Med. 18:1997;s1-s6. [Supplement].
2. Gille L., Nohl H. The existence of a lysosomal redox chain and the role of ubiquinone. Arch. Biochem. Biophys. 375:2000;347-354.
3. 10 and α-tocopherol content of mitochondria on the production of superoxide anion radicals. FASEB J. 14:2000;87-94.
4. Schöpfer F., Riobó N., Carreras M.C., Alvarez B., Radi R., Boveris A.et al. Oxidation of ubiquinol by peroxynitrite: implications for protection of mitochondria against nitrosative damage. Biochem. J. 349:2000;35-42.
5. Fontaine E., Ichas F., Bernardi P. A ubiquinone-binding site regulates the mitochondrial permeability transition pore. J. Biol. Chem. 273:1998;25734-25740.
6. 10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann. N. Y. Acad. Sci. 887:1999;31-47.
7. Kagan V.E., Fabisiak J.P., Quinn P.J. Coenzyme Q and vitamin E need each other as antioxidants. Protoplasma. 214:2000;11-18.
8. 10. Free Radic. Biol. Med. 26:1999;1375-1382.
9. Thomas S.R., Neuzil J., Stocker R. Cosupplementation with coenzyme Q prevents the prooxidant effect of α-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler. Thromb. Vasc. Biol. 16:1996;687-696.
10. Shi H., Noguchi N., Niki E. Comparative study on dynamics of antioxidative action of α-tocopherol hydroquinone, ubiquinol, and α-tocopherol against lipid peroxidation. Free Radic. Biol. Med. 26:1999;1375-1382.
11. 10 and remacemide in Huntington's disease. Neurology. 57:2001;397-404.
12. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59:2002;1541-1550.
13. 10 in congestive cardiomyopathy. Am. J. Ther. 4:1997;66-72.
14. 10 in apolipoprotein E gene knockout mice. Free Radic. Biol. Med. 29:2000;295-305.
15. 10 supplementation on mitochondrial function after myocardial ischemia reperfusion. J. Surg. Res. 102:2002;221-228.
16. 10. Biochem. Biophys. Res. Commun. 296:2002;255-260.
17. Yamashita S., Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal. Biochem. 250:1997;66-73.
18. Lagendijk J., Ubbink J.B., Delport R., Vermaak W.J., Human J.A. Ubiquinol/ubiquinone ratio as a marker of oxidative stress in coronary artery disease. Res. Commun. Mol. Pathol. Pharmacol. 95:1997;11-20.
19. Kontush A., Reich A., Baum K., Spranger T., Finckh B., Kohlschutter A.et al. Plasma ubiquinol-10 is decreased in patients with hyperlipidemia. Atherosclerosis. 129:1997;119-126.
20. Zierz S., Jahns G., Jerusalem F. Coenzyme Q in serum and muscle of 5 patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus. J. Neurol. 236:1989;97-101.
21. 10 deficiency. Neurology. 48:1997;1238-1243.
22. 10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 42:1997;261-264.
23. 10 and vitamin E in Juvenile Neuronal Ceroid-lipofuscinosis (JNCL). Mol. Aspects Med. 18:1997;s259-s262. [Supplement].
24. 10 in Parkinson's disease. J. Neural Transm. 107:2000;41-48.
25. 10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Res. Bull. 56:2001;405-410.
26. 10 deficiency. Neurology. 56:2001;849-855.
27. Molina J.A., de Bustos F., Ortiz S., Del Ser T., Seijo M., Benito-Leon J.et al. Serum levels of coenzyme Q in patients with Lewy body disease. J. Neural Transm. 109:2002;1195-1201.
28. 10 in animal models and a serious deficiency in patients with cancer. Biochem. Biophys. Res. Commun. 234:1997;296-299.
29. 10 in plasma and erythrocytes: comparison of antioxidant levels in healthy probands after oral supplementation and in patients suffering from sickle cell anemia. Clin. Chim. Acta. 326:2002;155-161.
30. de Cavanagh E.M., Honegger A.E., Hofer E., Bordenave R.H., Bullorsky E.O., Chasseing N.A.et al. Higher oxidation and lower antioxidant levels in peripheral blood plasma and bone marrow plasma from advanced cancer patients. Cancer. 94:2002;3247-3251.
31. 10 in uremic patients on chronic hemodialysis. Nephron. 66:1994;153-156.
32. 10, vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications. Clin. Chim. Acta. 292:2000;81-91.
33. Hubner C., Hoffmann G.F., Charpentier C., Gibson K.M., Finckh B., Puhl H.et al. Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency. Pediatr. Res. 34:1993;129-133.
34. Artuch R., Vilaseca M.A., Moreno J., Lanbruschini N., Cambra F.J., Campistol J. Decreased serum ubiquinone-10 concentrations in phenylketonuria. Am. J. Clin. Nutr. 70:1999;892-895.
35. Colome C., Artuch R., Vilaseca M.A., Sierra C., Brandi N., Cambra F.J.et al. Ubiquinone-10 content in lymphocytes of phenylketonuric patients. Clin. Biochem. 35:2002;81-84.
36. 10 fetal plasma levels. Fetal Diagn. Ther. 13:1998;127-130.
37. Hara K., Yamashita S., Fujisawa A., Ishiwa S., Ogawa T., Yamamoto Y. Oxidative stress in newborn infants with and without asphyxia as measured by plasma antioxidants and free fatty acids. Biochem. Biophys. Res. Commun. 257:1999;244-248.
38. MacDonnell M.G., Archbold G.P. Plasma ubiquinol/cholesterol ratios in patient with hyperlipidaemia, those with diabetes mellitus and in patients requiring dialysis. Clin. Chim. Acta. 253:1996;117-126.
39. 10 ratio as a possible marker for increased risk of atherosclerosis. BioFactors. 9:1999;231-240.
40. Yamamoto Y., Yamashita S., Fujisawa A., Kokura S., Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem. Biophys. Res. Commun. 247:1998;166-170.
41. 10 in patients with bronchial asthma. Allergy. 57:2002;811-814.
42. Morrison J.A., de Groot I., Edwards B.K., Kelly K.A., Rauh J.L., Mellies M.et al. Plasma cholesterol and triglyceride levels in 6775 school children, ages 6-17. Metabolism. 26:1977;1199-1211.
43. Morrison J.A., de Groot I., Edwards B.K., Kelly K.A., Mellies M.J., Khoury P.et al. Lipids and lipoproteins in 927 schoolchildren, ages 6-17 years. Pediatrics. 62:1978;990-995.
44. Morrison J.A., Kelly K., Horvitz R., Khoury P., Laskarzewski P.M., Mellies M.J.et al. Parent-offspring and sibling lipid and lipoprotein associations during and after sharing of household environments: the Princeton School District Family Study. Metabolism. 31:1982;158-167.
45. 10 in human plasma. Clin. Chem. 47:2001;256-265.
46. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total cholesterol. Clin. Chem. 20:1974;470-475.
47. +2 precipitation procedure for quantitation of high-density lipoprotein cholesterol. Cooper G.R. Selected Methods of Clinical Chemistry. vol. 10:1983;91-99 American Association for Clinical Chemistry, Washington, DC.
48. Spayd R.W., Bruschi B., Burdick B.A., Dappen G.M., Eikenberry J.N., Esders T.W.et al. Multilayer film elements for clinical analysis: applications to representative chemical determinations. Clin. Chem. 24:1978;1343-1350.
49. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
50. Horn P.S., Feng L., Li Y., Pesce A.J. Effect of outliers and nonhealthy individuals on reference interval estimation. Clin. Chem. 47:2001;2137-2145.
51. Box G.E.P., Cox D.R. An analysis of transformations. J. R. Stat. Soc. B26:1964;211-252.
52. Tukey J.W. Exploratory data analysis. 1977;Addison-Wesley, Reading, MA.
53. Horn P.S. A biweight prediction interval for random samples. J. Am. Stat. Assoc. 83:1988;249-256.
54. Horn P.S. Robust quantile estimators for skewed populations. Biometrika. 77:1990;631-636.
55. Horn P.S., Pesce A.J., Copeland B.E. A robust approach to reference interval estimation and evaluation. Clin. Chem. 44:1998;622-631.
56. Horn P.S., Pesce A.J., Copeland B.E. Reference interval computation using robust vs. parametric and nonparametric analyses. Clin. Chem. 45:1999;2284-2285.
57. Harrel F.E., Davis C.E. A new distribution-free quantile estimator. Biometrika. 69:1982;635-670.
58. Harris E.K., Boyd J.C. On dividing reference data into subgroups to produce separate reference ranges. Clin. Chem. 36:1990;265-270.
59. National Committee for Clinical Laboratory Standards: how to define and determine reference intervals in the clinical laboratory: approved guideline, NCCLS document C28-A and C28-A2, Villanova, PA, 1995, 2001 NCCLS.
60. 10: absorption, antioxidant properties, determinants, and plasma levels. Free Radic. Res. 36:2002;389-397.
61. 10 and differences in coronary heart disease risk in Asian Indians and Chinese. Free Radic. Biol. Med. 32:2002;132-138.
62. Sunesen V.H., Weber C., Hølmer G. Lipophilic antioxidants and polyunsaturated fatty acids in lipoprotein classes: distribution and interaction. Eur. J. Clin. Nutr. 55:2001;115-123.
63. Wallström P., Wirfält E., Lahmann P.H., Bullberg B., Janzon L., Berglund G. Serum concentrations of β-carotene and α-tocopherol are associated with diet, smoking, and general and central adiposity. Am. J. Clin. Nutr. 73:2001;777-785.
64. Kucharska J., Gvozdjakova A., Stejek M., Sotnikova R., Sumbalova Z. Adaptive changes of antioxidant status in development of experimental diabetes. Bratisl. Lek. Listy. 102:2001;515-519.
65. Ozata M., Mergen M., Oktenli C., Aydin A., Yavuz Sanisoglu S., Bolu E.et al. Increased oxidative stress and hypozincemia in male obesity. Clin. Biochem. 35:2002;627-631.
66. Davì G., Guagnano M.T., Ciabattoni G., Basili S., Falco A., Marinopiccoli M.et al. Platelet activation in obese women - role of inflammation and oxidant stress. JAMA. 288:2002;2008-2014.
67. 10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 45:2002;420-426.
68. 10 in Parkinson's disease. J. Neural Transm. 107:2000;41-48.
69. Pich M.M., Castagnoli A., Biondi A., Bernacchia A., Tazzari P.L., D'Aurelio M.et al. Ubiquinol and a coenzyme Q reducing system protect platelet mitochondrial function of transfusional buffy coats from oxidative stress. Free Radic. Res. 36:2002;429-436.
70. 10 estimated by HPLC with coulometric detection. Clin. Chim. Acta. 318:2002;127-131.